Buchumschlag

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Maaz Arif, Eric S. Orman
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
von: Vincent Mallet, et al.
Veröffentlicht: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
von: Ewan Forrest, et al.
Veröffentlicht: (2025)

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis
von: Luke D. Tyson, et al.
Veröffentlicht: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
von: Charlotte Mouliade, et al.
Veröffentlicht: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
von: Mary Yue Wang, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis
von: Mushfiqur R. Siddique, et al.
Veröffentlicht: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
von: Shupeng Zhao, et al.
Veröffentlicht: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
von: Stefan Mauss
Veröffentlicht: (2025)

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
von: Zainab Salman
Veröffentlicht: (2026)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
von: Gustavo Ayares, et al.
Veröffentlicht: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
von: Laura E. Telep, et al.
Veröffentlicht: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
von: Yu Jun Wong
Veröffentlicht: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
von: Catherine Jia Lin Tian, et al.
Veröffentlicht: (2024)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
von: Seren Gedallovich, et al.
Veröffentlicht: (2024)

Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids
von: Abdel‐Aziz Shaheen, et al.
Veröffentlicht: (2026)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
von: Jia‐Ling Wu, et al.
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
von: Wei‐Fan Hsu, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
von: Thomas Hoang, et al.
Veröffentlicht: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization
von: Pranab M. Barman
Veröffentlicht: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
von: Tanat Saeoui, et al.
Veröffentlicht: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
von: Marta Paula Pereira Coelho, et al.
Veröffentlicht: (2024)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2026)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Editorial: Hepatitis D Screening—DAS (Delta Virus Awareness and Screening) Approach in Primary Care
von: Noreen Singh, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
von: J. Ventre, et al.
Veröffentlicht: (2025)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
von: Miriam T. Levy
Veröffentlicht: (2026)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
von: Sarah Flatley
Veröffentlicht: (2026)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
von: Stine Johansen, et al.
Veröffentlicht: (2026)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
von: Luis Calzadilla Bertot, et al.
Veröffentlicht: (2025)

Editorial: Stopping NUCs—When to Restart NUCs for the Best Outcome?
von: Melanie Urbanek‐Quaing, et al.
Veröffentlicht: (2024)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
von: Shun‐Ichi Wakabayashi, et al.
Veröffentlicht: (2026)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
von: Yanxue Lin, et al.
Veröffentlicht: (2025)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
von: Christopher L. Bowlus, et al.
Veröffentlicht: (2025)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)